teaser
Bayer HealthCare has announced that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently US Food and Drug Administration (FDA) approved product Xofigo® (radium 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 – June 4, in Chicago, IL (USA).
These data, including the first presentation of the results from the pivotal Phase III DECISION trial of Nexavar in patients with radioactive iodine-refractory differentiated thyroid cancer, showcase Bayer’s commitment to developing effective treatments for difficult-to-treat cancers.
“Bayer’s presence at ASCO this year reflects both the strong foundation of our oncology franchise, heralded by the expanded clinical success of Nexavar, and the innovations we are continuing to deliver in tumor types with high unmet need,” said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development. “Since last year’s ASCO meeting, our oncology franchise has grown to include two additional products in three indications. We’re proud of this landmark year which is a result of our ongoing commitment to making bold investments in areas where we can truly make a difference for patients.”
Notable studies evaluating Bayer’s oncology products and compounds at ASCO include:
Sorafenib (Nexavar)
- Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial
- Abstract #4, Plenary Abstract Session
- Sunday, June 2, 3:20 – 3:35 PM, N Hall B1
- Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction
- Abstract #4126, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
- Sunday, June 2, 8:00 – 11:45 AM, S Hall A2
Regorafenib (Stivarga)
- Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.
- Abstract #10503, Oral Abstract Session: Sarcoma
- Monday, June 3, 3:45 – 4:00 PM, S100bc
- Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
- Abstract # 10551, General Poster Session: Sarcoma
- Saturday, June 1, 1:15 – 5:00 PM, S Hall A2
- Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study
- Abstract # 3637, General Poster Session: Gastrointestinal (Colorectal) Cancer
- Sunday, June 2, 8:00 – 11:45 AM, S Hall A2
- Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial
- Abstract # 3636, General Poster Session: Gastrointestinal (Colorectal) Cancer
- Sunday, June 2, 8:00 – 11:45 AM, S Hall A2
- Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial
- Abstract # TPS4163, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
- Sunday, June 2, 8:00 – 11:45 AM, S Hall A2
- Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer
- Abstract #3514, Poster Discussion Session: Gastrointestinal (Colorectal) Cancer
- Tuesday, June 4, 8:00 AM – 12:00 PM, S405
Radium 223 dichloride (Xofigo)
- Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study.
- Abstract #5021, Poster Discussion Session, Genitourinary (Prostate) Cancer
- Saturday, June 1, 8:00 AM – 12:00 PM, E450a, Poster Board #13
- Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
- Abstract #5060, General Poster Session: Genitourinary (Prostate) Cancer
- Monday, June 3, 8:00 – 11:45 AM, S Hall A2
- Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial
- Abstract #5068, General Poster Session: Genitourinary (Prostate) Cancer
- Monday, June 3, 8:00 – 11:45 AM, S Hall A2
- Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
- Abstract #5038, General Poster Session: Genitourinary (Prostate) Cancer
- Monday, June 3, 8:00 – 11:45 AM, S Hall A2
- Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes
- Abstract #5080, General Poster Session: Genitourinary (Prostate) Cancer
- Monday, June 3, 8:00 – 11:45 AM, S Hall A2
